Assessment of cognitive function and its predictors in patients with multiple sclerosis: a case-control study.
Addenbrooke Cognitive Assessment Battery
Cognitive function
Depression
Fatigue
Multiple sclerosis
Journal
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
ISSN: 1590-3478
Titre abrégé: Neurol Sci
Pays: Italy
ID NLM: 100959175
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
15
07
2022
accepted:
20
11
2022
pubmed:
29
11
2022
medline:
16
2
2023
entrez:
28
11
2022
Statut:
ppublish
Résumé
Cognitive dysfunction can be seen in patients with MS (PwMS) and has been gaining attention in recent years. This study aimed to assess cognitive function and its determinants in PwMS using Addenbrooke Cognitive Assessment Battery (ACE-R). This case-control study was conducted at an outpatient MS clinic in Istanbul. The sample consisted of 60 consecutive patients with definite MS and 60 matched controls. Cognitive function was evaluated by using the ACE-R. Subjective cognitive function, anxiety, depression, and fatigue were evaluated by validated scales. The mean age of the patients was 38.8, and the time since diagnosis was nine years. The majority of the patients had relapsing-remitting MS. Compared to age, sex, and education-matched healthy controls, all ACE-R scores, attention/orientation (p = 0.020), memory (p = 0.003), verbal fluency (p = 0.002), language (p = 0.002), visuospatial (p = 0.001), and general cognitive functioning (p < 0.001), were found to be lower in PwMS. The patients obtained the lowest scores in memory and fluency and the highest in the visuospatial domain. Age, education, mobility, subjective cognitive dysfunction, anxiety, depression, and fatigue were associated with cognitive test scores. However, only education, depression, and fatigue remained significant in the multivariable analysis. This study revealed impaired domains of cognitive functioning and its predictors in PwMS. Understanding cognitive dysfunction and its predictors in PwMS may enable healthcare providers to identify patients who might benefit from interventions to improve cognitive function. Assessment of PwMS at outpatient clinics with a practical cognitive test that does not require special competence can be suggested.
Identifiants
pubmed: 36443543
doi: 10.1007/s10072-022-06524-8
pii: 10.1007/s10072-022-06524-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1009-1016Subventions
Organisme : Istanbul Üniversitesi-Cerrahpasa
ID : BEK-2017-26529
Informations de copyright
© 2022. Fondazione Società Italiana di Neurologia.
Références
Patti F, Nicoletti A, Messina S, Bruno E, Fermo SL, Quattrocchi G et al (2015) Prevalence and incidence of cognitive impairment in multiple sclerosis: a population-based survey in Catania. Sicily J Neurol 262(4):923–930. https://doi.org/10.1007/s00415-015-7661-3
doi: 10.1007/s00415-015-7661-3
pubmed: 25663413
Ozakbas S, Turkoglu R, Tamam Y, Terzi M, Taskapilioglu O, Yucesan C et al (2018) Prevalence of and risk factors for cognitive impairment in patients with relapsing-remitting multiple sclerosis: multi-center, controlled trial. Mult Scler Relat Disord 22:70–76. https://doi.org/10.1016/j.msard.2018.03.009
doi: 10.1016/j.msard.2018.03.009
pubmed: 29605801
Branco M, Ruano L, Portaccio E, Goretti B, Niccolai C, Patti F et al (2019) Aging with multiple sclerosis: prevalence and profile of cognitive impairment. Neurol Sci 40(8):1651–1657. https://doi.org/10.1007/s10072-019-03875-7
doi: 10.1007/s10072-019-03875-7
pubmed: 31011932
Skorve E, Lundervold AJ, Torkildsen Ø, Myhr KM (2020) A two-year longitudinal follow-up of cognitive performance assessed by BICAMS in newly diagnosed patients with MS. Mult Scler Relat Disord 46:102577. https://doi.org/10.1016/j.msard.2020.102577
doi: 10.1016/j.msard.2020.102577
pubmed: 33296975
Sundgren M, Maurex L, Wahlin Å, Piehl F, Brismar T (2013) Cognitive impairment has a strong relation to nonsomatic symptoms of depression in relapsing-remitting multiple sclerosis. Arch Clin Neuropsychol 28(2):144–155. https://doi.org/10.1093/arclin/acs113
doi: 10.1093/arclin/acs113
pubmed: 23291310
Golan D, Doniger GM, Wissemann K, Zarif M, Bumstead B, Buhse M et al (2018) The impact of subjective cognitive fatigue and depression on cognitive function in patients with multiple sclerosis. Mult Scler 24(2):196–204. https://doi.org/10.1177/1352458517695470
doi: 10.1177/1352458517695470
pubmed: 28273778
Brochet B, Ruet A (2019) Cognitive impairment in multiple sclerosis with regards to disease duration and clinical phenotypes. Front Neurol 20(10):261. https://doi.org/10.3389/fneur.2019.00261
doi: 10.3389/fneur.2019.00261
Kobelt G, Thompson A, Berg J, Gannedahl M, Eriksson J, MSCOI study group; European Multiple Sclerosis Platform (2017) New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler 23(8):1123–1136. https://doi.org/10.1177/1352458517694432
doi: 10.1177/1352458517694432
pubmed: 28273775
pmcid: 5476197
Oreja-Guevara C, Kobelt G, Berg J, Capsa D, Eriksson J, European Multiple Sclerosis Platform (2017) New insights into the burden and costs of multiple sclerosis in Europe: results for Spain. Mult Scler 23(2_suppl):166–178. https://doi.org/10.1177/1352458517708672
doi: 10.1177/1352458517708672
pubmed: 28643597
Biernacki T, Sandi D, Kincses ZT, Füvesi J, Rózsa C, Mátyás K et al (2019) Contributing factors to health-related quality of life in multiple sclerosis. Brain Behav 9(12):e01466. https://doi.org/10.1002/brb3.1466
doi: 10.1002/brb3.1466
pubmed: 31709732
pmcid: 6908891
Renner A, Baetge SJ, Filser M, Penner IK (2020) Working ability in individuals with different disease courses of multiple sclerosis: factors beyond physical impairment. Mult Scler Relat Disord 46:102559. https://doi.org/10.1016/j.msard.2020.102559
doi: 10.1016/j.msard.2020.102559
pubmed: 33035965
Benedict RHB, Amato MP, DeLuca J, Geurts JJG (2020) Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues. Lancet Neurol 19(10):860–871. https://doi.org/10.1016/S1474-4422(20)30277-5
doi: 10.1016/S1474-4422(20)30277-5
pubmed: 32949546
Figlus M, Obrembska M, Miller E, Głąbiński A (2018) Addenbrooke’s Cognitive Examination-III (ACE-III) test as a new potential tool for screening of cognitive dysfunctions in the course of multiple sclerosis. Adv Psychiatry Neurol/Postępy Psychiatrii i Neurologii 27(4):281–288. https://doi.org/10.5114/ppn.2018.79556
doi: 10.5114/ppn.2018.79556
Mioshi E, Dawson K, Mitchell J, Arnold R, Hodges JR (2006) The Addenbrooke’s Cognitive Examination Revised (ACE-R): a brief cognitive test battery for dementia screening. Int J Geriatr Psychiatry 21(11):1078–1085. https://doi.org/10.1002/gps.1610
doi: 10.1002/gps.1610
pubmed: 16977673
Velayudhan L, Ryu SH, Raczek M, Philpot M, Lindesay J, Critchfield M, Livingston G (2014) Review of brief cognitive tests for patients with suspected dementia. Int Psychogeriatr 26(8):1247–1262. https://doi.org/10.1017/S1041610214000416
doi: 10.1017/S1041610214000416
pubmed: 24685119
pmcid: 4071993
Amaral-Carvalho V, Caramelli P (2012) Normative data for healthy middle-aged and elderly performance on the Addenbrooke Cognitive Examination-Revised. Cognitive Behav Neurol 25(2):72–6. https://doi.org/10.1097/WNN.0b013e318259594b
doi: 10.1097/WNN.0b013e318259594b
Wei Q, Chen X, Zheng Z, Huang R, Guo X, Cao B, Bak TH, Shang H (2015) Screening for cognitive impairment in a Chinese ALS population. Amyotroph Lateral Scler Frontotemporal Degener 16(1–2):40–5. https://doi.org/10.3109/21678421.2014.966311
doi: 10.3109/21678421.2014.966311
pubmed: 25309978
Petrusic I, Pavlovski V, Savkovic Z, Vucinic D, Filipovic B, Jancic J (2017) Addenbrooke’s cognitive examination test for brief cognitive assessment of adolescents suffering from migraine with aura. Acta Neurol Belg 117:97–102. https://doi.org/10.1007/s13760-016-0655-9
doi: 10.1007/s13760-016-0655-9
pubmed: 27255917
Mani A, Chohedri E, Ravanfar P, Mowla A, Nikseresht A (2018) Efficacy of group cognitive rehabilitation therapy in multiple sclerosis. Acta Neurol Scand. 137(6):589–597. https://doi.org/10.1111/ane.12904
doi: 10.1111/ane.12904
pubmed: 29411360
Elshebawy H, Fahmy EM, Elfayoumy NM, Abdelalim AM, Ismail RS (2021) Clinical predictors to cognitive impairment in multiple sclerosis patients. Egyptian J Neurol Psychiatry Neurosurgery 57(38):1–6. https://doi.org/10.1186/s41983-021-00292-6
doi: 10.1186/s41983-021-00292-6
Yıldız S, & Gürvit H (2011) Addenbrooke Kognitif Değerlendirme Bataryası’nın Türk populasyonu için adaptasyonu (Adaptation of Addenbrooke’s Cognitive Examination-Revised to Turkish population). Istanbul University Institute of Health Sciences, Department of Neuroscience, Unpublished Master Dissertation, Istanbul
Benedict RH, Munschauer F, Linn R, Miller C, Murphy E, Foley F et al (2003) Screening for multiple sclerosis cognitive impairment using a self-administered 15-item questionnaire. Mult Scler 9(1):95–101. https://doi.org/10.1191/1352458503ms861oa
doi: 10.1191/1352458503ms861oa
pubmed: 12617275
Aydemir Ö, Güvenir T, Kuey L, Kültür S (1997) Validity and reliability of Turkish version of Hospital Anxiety and Depression Scale. Turk Psikiyatri Derg 8(4):280–287
Armutlu K, Keser I, Korkmaz N, Akbiyik DI, Sümbüloğlu V, Güney Z et al (2007) Psychometric study of Turkish version of Fatigue Impact Scale in multiple sclerosis patients. J Neurol Sci 255(1–2):64–68. https://doi.org/10.1016/j.jns.2007.01.073
doi: 10.1016/j.jns.2007.01.073
pubmed: 17337007
Gencay-Can A, Can SS (2012) Validation of the Turkish version of the fatigue severity scale in patients with fibromyalgia. Rheumatol Int 32(1):27–31. https://doi.org/10.1007/s00296-010-1558-1553
doi: 10.1007/s00296-010-1558-1553
pubmed: 20658235
Patti F, Amato MP, Trojano M, Bastianello S, Tola MR, Goretti B, COGIMUS Study Group et al (2009) Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the cognitive impairment in multiple sclerosis (COGIMUS) study. Mult Scler. 15(7):779–788. https://doi.org/10.1177/1352458509105544
doi: 10.1177/1352458509105544
pubmed: 19542262
Scutt P, Blackburn D, Krishnan K, Ballard C, Burns A, Ford GA et al (2015) Baseline characteristics, analysis plan and report on feasibility for the prevention of decline in cognition after stroke trial (PODCAST). Trials 7(16):509. https://doi.org/10.1186/s13063-015-1033-1032
doi: 10.1186/s13063-015-1033-1032
Uysal-Cantürk P, Hanağası HA, Bilgiç B, Gürvit H, Emre M (2018) An assessment of Movement Disorder Society Task Force diagnostic criteria for mild cognitive impairment in Parkinson’s disease. Eur J Neurol 25:148–153. https://doi.org/10.1111/ene.13467
doi: 10.1111/ene.13467
pubmed: 28941002
Dalpubel D, Rossi PG, de Almeida ML, Ribeiro EB, Araújo R, de Andrade LP et al (2019) Subjective memory complaint and its relationship with cognitive changes and physical vulnerability of community-dwelling older adults. Dement Neuropsychol 13(3):343–349. https://doi.org/10.1590/1980-57642018dn13-030012
doi: 10.1590/1980-57642018dn13-030012
pubmed: 31555408
pmcid: 6753904
Korten V, Ay U, Harı E, Tigen Tükenmez E, Gencer S, Akça Kalem S et al (2021) Prevalence of HIV-associated neurocognitive disorder (HAND) in Turkey and assessment of Addenbrooke’s Cognitive Examination Revised (ACE-R) test as a screening tool. HIV Med 22(1):60–66. https://doi.org/10.1111/hiv.12957
doi: 10.1111/hiv.12957
pubmed: 32964651
Yoshii F, Takagi S, Nagata E, Hasegawa Y, Kunika N, Maki F et al (2015) Cognitive impairment of Japanese multiple sclerosis patients: follow-up study using BRB-N assessment tool. J Neurol Sci 359(1–2):323–327. https://doi.org/10.1016/j.jns.2015.11.002
doi: 10.1016/j.jns.2015.11.002
pubmed: 26671136
Skorve E, Lundervold AJ, Torkildsen Ø, Myhr KM (2019) The Norwegian translation of the brief international cognitive assessment for multiple sclerosis (BICAMS). Mult Scler Relat Disord 36:101408. https://doi.org/10.1016/j.msard.2019.101408
doi: 10.1016/j.msard.2019.101408
pubmed: 31610403
Wojtowicz M, Omisade A, Fisk J (2013) Indices of cognitive dysfunction in relapsing-remitting multiple sclerosis: intra-individual variability, processing speed, and attention network efficiency. J Int Neuropsychol Soc 19(5):551–558. https://doi.org/10.1017/S13556177130000274
doi: 10.1017/S13556177130000274
pubmed: 23425598
D’hooghe MB, De Cock A, Van Remoortel A, Benedict RHB, Eelen P, Peeters E et al (2019) Correlations of health status indicators with perceived neuropsychological impairment and cognitive processing speed in multiple sclerosis. Mult Scler Relat Disord. 39:101904. https://doi.org/10.1016/j.msard.2019.101904
doi: 10.1016/j.msard.2019.101904
pubmed: 31981931
Hughes AJ, Bhattarai JJ, Paul S, Beier M (2019) Depressive symptoms and fatigue as predictors of objective-subjective discrepancies in cognitive function in multiple sclerosis. Mult Scler Relat Disord 30:192–197. https://doi.org/10.1016/j.msard.2019.01.055
doi: 10.1016/j.msard.2019.01.055
pubmed: 30797133
pmcid: 7282884
Almeida L, Szklo A, Sampaio M, Souza M, Martins LF, Szklo M, Caixeta R (2012) Global Adult Tobacco Survey data as a tool to monitor the WHO Framework Convention on Tobacco Control (WHO FCTC) implementation: the Brazilian case. Int J Environ Res Public Health 9(7):2520–2536. https://doi.org/10.3390/ijerph9072520
doi: 10.3390/ijerph9072520
pubmed: 22851957
pmcid: 3407918
Bruce JM, Hancock LM, Arnett P, Lynch S (2010) Treatment adherence in multiple sclerosis: association with emotional status, personality, and cognition. J Behav Med 33(3):219–227. https://doi.org/10.1007/s10865-010-9247-y
doi: 10.1007/s10865-010-9247-y
pubmed: 20127401
Pinter D, Sumowski J, DeLuca J, Fazekas F, Pichler A, Khalil M et al (2014) Higher education moderates the effect of T2 lesion load and third ventricle width on cognition in multiple sclerosis. PLoS One 9(1):e87567. https://doi.org/10.1371/journal.pone.0087567
doi: 10.1371/journal.pone.0087567
pubmed: 24475309
pmcid: 3903771
Rimkus CM, Avolio IMB, Miotto EC, Pereira SA, Mendes MF, Callegaro D et al (2018) The protective effects of high-education levels on cognition in different stages of multiple sclerosis. Mult Scler Relat Disord 22:41–48. https://doi.org/10.1016/j.msard.2018.03.001
doi: 10.1016/j.msard.2018.03.001
pubmed: 29554549
Hegedüs K, Kárpáti J, Iljicsov A, Simó M (2019) Neuropsychological characteristics of benign multiple sclerosis patients: a two-year matched cohort study. Mult Scler Relat Disord 35:150–155. https://doi.org/10.1016/j.msard.2019.07.022
doi: 10.1016/j.msard.2019.07.022
pubmed: 31376686